公开(公告)号：US10261101B2

公开(公告)日：2019-04-16

申请号：US15803252

申请日：2017-11-03

Applicant: ZORA BIOSCIENCES OY

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Riikka Katainen

IPC: G01N33/92

Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

公开(公告)号：US20170082644A1

公开(公告)日：2017-03-23

申请号：US15363376

申请日：2016-11-29

Applicant: Zora Biosciences OY

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Riikka Katainen ,  Minna Janis ,  Kirill Tarasov

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2570/00 ,  G01N2800/10 ,  G01N2800/2871 ,  G01N2800/325

Abstract: The present invention inter alia provides a method, and uses thereof, of predicting statin-induced muscle toxicity or its complications, such as myalgia, myopathy and rhabdomyolysis, by detecting the lipid concentrations or lipid-lipid concentration ratios of a biological sample and comparing them to a control. This method has identified lipid markers that are more specific and sensitive in detecting these statin-induced muscle toxicity than the currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, statin-induced muscle toxicity. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of statin-induced muscle toxicity.

公开(公告)号：US09459264B2

公开(公告)日：2016-10-04

申请号：US14712422

申请日：2015-05-14

Applicant: ZORA BIOSCIENCES OY

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Riika Katainen

IPC: G01N33/92

CPC classification number: G01N33/92 ,  A61K31/366 ,  A61K31/397 ,  G01N2405/04 ,  G01N2570/00 ,  G01N2800/32 ,  G01N2800/323 ,  G01N2800/324 ,  G01N2800/325 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.

公开(公告)号：US09841431B2

公开(公告)日：2017-12-12

申请号：US14875087

申请日：2015-10-05

Applicant: ZORA BIOSCIENCES OY

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Riikka Katainen

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2405/04 ,  G01N2405/06 ,  G01N2570/00 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

公开(公告)号：US20170160264A1

公开(公告)日：2017-06-08

申请号：US15371661

申请日：2016-12-07

Applicant: ZORA BIOSCIENCES, OY

Inventor： Marko Sysi-Aho ,  Mika Hilvo ,  Kim Ekroos ,  Reini Hurme ,  Reijo Laaksonen ,  Virve Väisänen

IPC: G01N33/49

CPC classification number: G01N33/492 ,  G01N33/92 ,  G01N2800/2871 ,  G01N2800/324 ,  G01N2800/52

Abstract: The present invention inter alia provides a method, and use thereof, of predicting CV events such as AMI, ACS, stroke, and CV death by determining the concentration of at least one ceramide of Formula I or one lysophospholipid of Formula II and/or III and at least one lysophospholipid of Formula IV, V, VI, VII and/or VIII in a biological sample and comparing those concentrations to a control. Finding an increased concentration of the at least one Formula I ceramide or Formula II and/or III lysophospholipid and a decreased concentration of the at least one Formula IV, V, VI, VII and/or VIII lysophospholipid indicates that the subject has an increased risk of developing one or more CV events. The present disclosure also provides a method, and use thereof, of diagnosing subjects suffering acute ischemia. Also provided are kits and compositions comprising the same for use in predicting and/or diagnosing CV events.

公开(公告)号：US20150260737A1

公开(公告)日：2015-09-17

申请号：US14722964

申请日：2015-05-27

Applicant: Zora Biosciences OY

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Riikka Katainen

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2570/00 ,  G01N2800/042 ,  G01N2800/32 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/70

Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

Abstract translation: 本发明尤其提供了通过检测生物样品的脂质浓度或脂质比例并将其与对照进行比较来预测严重的CVD并发症如AMI或CVD死亡的方法及其用途，并且鉴定了特异性脂质标记物 在预测这些CVD并发症方面比目前使用的临床标志物更具体和灵敏。 还提供了针对所述脂质的抗体及其用于预测，诊断，预防和/或治疗CVD并发症的用途。 本发明另外涉及包含脂质和/或其抗体的试剂盒，用于CVD并发症的预测和/或诊断。

公开(公告)号：US09052328B2

公开(公告)日：2015-06-09

申请号：US14356594

申请日：2012-11-07

Applicant: Zora Biosciences OY

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Minna Jänis ,  Riikka Katainen ,  Kirill Tarasov

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N2570/00 ,  G01N2800/042 ,  G01N2800/32 ,  G01N2800/324 ,  G01N2800/50 ,  G01N2800/70

Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided are antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

Abstract translation: 本发明尤其提供了通过检测生物样品的脂质浓度或脂质比例并将其与对照进行比较来预测严重的CVD并发症如AMI或CVD死亡的方法及其用途，并且鉴定了特异性脂质标记物 在预测这些CVD并发症方面比目前使用的临床标志物更具体和灵敏。 还提供了针对所述脂质的抗体及其用于预测，诊断，预防和/或治疗CVD并发症的用途。 本发明另外涉及包含脂质和/或其抗体的试剂盒，用于CVD并发症的预测和/或诊断。

公开(公告)号：US10955427B2

公开(公告)日：2021-03-23

申请号：US16291845

申请日：2019-03-04

Applicant: ZORA BIOSCIENCES OY

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Riikka Katainen

IPC: G01N33/92

Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.

公开(公告)号：US20210003598A1

公开(公告)日：2021-01-07

申请号：US16715801

申请日：2019-12-16

Applicant: Zora Biosciences OY

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Riikka Katainen

IPC: G01N33/92 ,  A61K31/366 ,  A61K31/397

Abstract: The present invention inter alia provides a method, and use thereof, of diagnosing and/or predicting atherosclerosis or CVD by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in detecting and predicting atherosclerosis and CVD than currently utilized clinical markers. Also provided is an antibody towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating atherosclerosis or CVD. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of atherosclerosis or CVD.

公开(公告)号：US20200003794A1

公开(公告)日：2020-01-02

申请号：US16291845

申请日：2019-03-04

Applicant: ZORA BIOSCIENCES OY

Inventor： Reijo Laaksonen ,  Kim Ekroos ,  Reini Hurme ,  Riikka Katainen

IPC: G01N33/92

Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.